Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 11/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.44 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | TPMT | P51580 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12154699 | 0.87 | ERN1 (0.54) | ERN1KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL8321673 | 0.86 | TPMT (0.40) | ERN1KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL1534545 | 0.85 | ALDH1A1 (0.53) | ERN1KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL16369624 | 0.83 | ERN1 (0.50) | ERN1KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL14092107 | 0.82 | ALDH1A1 (0.50) | ERN1KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL789758 | 0.82 | MAPT (0.44) | ERN1KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL7510757 | 0.82 | ERN1 (0.74) | ERN1KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL4437002 | 0.81 | ERN1 (0.55) | ERN1KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL9275679 | 0.81 | ALDH1A1 (0.49) | ERN1KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL69641 | 0.80 | TPMT (0.49) | ALDH1A1CYP3A4MAPTALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2956437-B1 | ALBICIDIN DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | UNIV BERLIN TECH (DE) | 2023-05-10 | — | — | EP | disclosed |
| EP-2956437-B1 | ALBICIDIN DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | UNIV BERLIN TECH (DE) | 2023-05-10 | — | — | EP | disclosed |
| US-11427542-B2 | Compounds for treatment of cardiac arrhythmias and heart failure | ELEX BIOTECH, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-11225503-B2 | Crystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2022-01-18 | — | — | US | disclosed |
| US-11225503-B2 | Crystobactamides | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2022-01-18 | — | — | US | disclosed |
| EP-3224238-B1 | NOVEL CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2021-08-11 | — | — | EP | disclosed |
| US-20210139429-A1 | COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE | ELEX BIOTECH, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| EP-3019615-B1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2021-04-07 | — | — | EP | disclosed |
| EP-3019615-B1 | CYSTOBACTAMIDES | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2021-04-07 | — | — | EP | disclosed |
| CN-105793424-B | Ascomycetes amides | 亥姆霍兹感染研究中心有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20060229333-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-12 | — | — | US | disclosed |
| US-7109212-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2006-09-19 | — | — | US | disclosed |
| EP-1601348-A2 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE, INC. (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20050165050-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2005-07-28 | — | — | US | disclosed |
| US-6897224-B2 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2005-05-24 | — | — | US | disclosed |
| EP-1492771-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | MATEON THERAPEUTICS, INC. | 2004-12-02 | — | — | US | disclosed |
| WO-2004078126-A2 | COMPOSITIONS AND METHODS WITH ENHANCED THERAPEUTIC ACTIVITY | OXIGENE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040116694-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | SCHERING AG (DE) | 2004-06-17 | — | — | US | disclosed |
| WO-2003082827-A1 | QUINOLINE AND ISOQUINOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | NQO1, MKI67, COMT | ERN1 3895/4885KDM4E 1518/4885ALDH1A1 553/4885 |
| US-11225503-B2 | Crystobactamides | PKD2, SLC7A11, CTH | ERN1 3052/4885KDM4E 3912/4885ALDH1A1 2778/4885 |
| US-20210139429-A1 | COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE | RYR2, RYR1, CACNA1F | ERN1 2925/4885KDM4E 3952/4885ALDH1A1 2527/4885 |
| US-20060229333-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | NFKBIA, IL1B, IRF3 | ERN1 1763/4885KDM4E 3072/4885ALDH1A1 1538/4885 |
| US-20050165050-A1 | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | NFKBIA, IL1B, IRF3 | ERN1 1763/4885KDM4E 3072/4885ALDH1A1 1538/4885 |
| US-11427542-B2 | Compounds for treatment of cardiac arrhythmias and heart failure | RYR2, RYR1, CACNA1F | ERN1 2925/4885KDM4E 3952/4885ALDH1A1 2527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.